Diabeloop’s latest automated insulin delivery (AID) system, DBLG2, has been approved for use with compatible devices, and is being slowly rolled out across European countries. The algorithm currently works with Kaleido, a small and colorful tubed pump, and the Dexcom G7 continuous glucose monitor (CGM), with additional configurations in the works.
The DBGL2 algorithm is self-learning, meaning it will adapt and customize to each user. It automatically adjusts insulin delivery in real time based on glucose readings. Most notably, meal announcements are not necessary, but if entered will help with glucose control. DBLG2 runs off a smartphone compatible app, eliminating the need for a separate controller. The app is available on Android devices with an iOS version coming soon.
Kaleido is currently available in France, Germany, and the Netherlands. It has a small, sleek design you can attach directly to your body with a Velcro-like patch. There are two tubing options: a short 2-inch tube or a longer 12-inch option. The current DBGL1 algorithm works with Kaleido and the Dexcom G6 with several customizable features including personal glycemic targets, meal-time alerts, and pre-scheduled activity.
The Kaleido insulin pump is a colorful patch pump with a short tube. (source: ViCentra)
Diabeloop will continue to support DBLG1 for the time being and will create transition systems for those using the previous generation. The company’s CEO stated, “we are empowering patients with unprecedented choice, discretion, and optimal glycemic control.”
For ViCentra, Kaleido’s parent company, these algorithmic developments come with the push for scalability and growth across more European countries and the anticipated launch of Kaleido 2. This version of the pump will be 10% smaller with longer battery life. It’s expected to hit the European market in early 2027 with hopes to release it in the US market.
Diabeloop has also partnered with Sequel Med Tech to bring DBLG2 to the twiist pump, which would give U.S. users the option to use its algorithm.
Would you consider this algorithm? Let us know your thoughts in the comments.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking exclusive Live Q&As, giveaways, stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a healthcare team before making changes to your treatment.